The impact of 5-alpha reductase inhibitor vs. alpha-1 adrenergic receptor antagonists on course of prostate premalignant conditions
| Autor: | Piotr Bryniarski, Andrzej Paradysz, Mieczysław Fryczkowski, Maciej Szczębara |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Medicine (miscellaneous) Reductase Pharmacology Gastroenterology General Biochemistry Genetics and Molecular Biology 5 Alpha-Reductase Inhibitor chemistry.chemical_compound Prostate cancer 5-alpha Reductase Inhibitors Prostate Internal medicine Internal Medicine medicine Neoplasm Humans Pharmacology (medical) Genetics (clinical) Alpha-1 adrenergic receptor Aged Retrospective Studies Atypical small acinar proliferation medicine.diagnostic_test business.industry Finasteride Prostatic Neoplasms Middle Aged medicine.disease medicine.anatomical_structure chemistry Reviews and References (medical) Adrenergic alpha-1 Receptor Antagonists business Precancerous Conditions |
| Zdroj: | Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 23(1) |
| ISSN: | 1899-5276 |
| Popis: | BACKGROUND Prostate intraepithelial neoplasm and atypical small acinar proliferation are considered prostate premalignant conditions. Such a diagnosis impacts further follow-up significantly as early detection of prostate cancer is of utmost importance. alpha-1 adrenergic receptor antagonists (i.e. doxazosiunum) and inhibitors of 5-alpha reductase (Finasteride) showed some efficacy in prevention of prostate cancer development. OBJECTIVES To assess the impact of both above mentioned drugs on prostate premalignant conditions. MATERIAL AND METHODS From January 2008 till September 2012, 213 patients with one of the above mentioned premalignant condition were retrospectively evaluated. after diagnosis they were assigned to group 1 (n-126)- treated with Finasteride or to group 2 (n-87)-treated with doxazosinum. every 6-7 months rebiopsies were conducted in each patient. Rate of remission and progression was assessed. RESULTS In comparison between group 1 and 2 the rate of remission was 35.7% (n-45) vs. 18.4% (n-16) (p = 0.005). In terms of progression, the difference between 1st and 2nd group of patients was 7.1% (n-9) vs. 5.7% (n-5) (p = 0.68). CONCLUSIONS Remission of prostate premalignant condition is efficacious with Finasteride and not with doxazosinum. However, in terms of progression there were no differences among both drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|